ArticleTransfusion2026
Maternal-fetal platelet alloimmunization: Identification of risk factors for severe neonatal thrombocytopenia.
Article in Transfusion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFeto-maternal platelet alloimmunization (FNAIT) is a rare condition (1 in 1500 live pregnancies), most commonly diagnosed based on clinical neonatal hemorrhagic manifestations, which can vary in severity. The aim of our study was to identify risk factors for severe fetal/neonatal thrombocytopenia in cases of FNAIT. MATERIALS AND
methodsA retrospective study from 1993 to 2022 of pregnancies characterized by FNAIT. Data collected included patient characteristics, management of the pregnancies, and neonatal characteristics. Comparisons regarding pregnancy management and neonatal data were made between "index cases" and "subsequent pregnancies," as well as between neonates with severe thrombocytopenia and those with no thrombocytopenia or moderate thrombocytopenia.
resultsSeventy-one patients were included in our study, corresponding to 119 pregnancies. Mothers of neonates with severe thrombocytopenia had a higher history of previous pregnancies characterized by severe neonatal thrombocytopenia (100.0% vs. 75.9%, p = .03). The FNAIT mainly involved the anti-HPA-1a system (75.0% vs. 54.5%, p = .02), and fewer treatments with IVIG were administered during pregnancy (6.6% vs. 34.1%, p < .001).
conclusionFNAIT must be identified and appropriately managed to limit its potentially dramatic consequences, including fetal/neonatal death. Based on the patient's history, risk stratification for the occurrence of severe FNAIT in future pregnancies should be performed to tailor its management accordingly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.